Learn about cystic fibrosis, a genetic disorder that affects the lungs, pancreas, and other organs, and how to treat and live with this chronic disease.
CF is a rare genetic disease found in about 30,000 people in the U.S. If you have CF or are considering testing for it, knowing about the role of genetics in CF can help you make informed decisions about your health care.
If you or your child has just been diagnosed with cystic fibrosis, or your doctor has recommended testing for CF, you may have many questions.
Diagnosing CF is a multistep process. A complete diagnostic evaluation should include a newborn screening, a sweat chloride test, a genetic or carrier test, and a clinical evaluation at a CF Foundation-accredited care center.
Raising a child with cystic fibrosis can bring up many questions because CF affects many aspects of your child’s life. Here you’ll find resources to help you manage your child’s daily needs and find the best possible CF care.
Living with cystic fibrosis comes with many challenges, including medical, social, and financial. By learning more about how you can manage your disease every day, you can ultimately help find a balance between your busy lifestyle and your CF care.
People with CF are living longer, healthier lives than ever before. As an adult with CF, you may reach key milestones you might not have considered. Planning for these life events requires careful thought as you make decisions that may impact your life.
People with cystic fibrosis are living longer and more fulfilling lives, thanks in part to specialized CF care and a range of treatment options.
Cystic Fibrosis Foundation-accredited care centers provide expert care and specialized disease management to people living with cystic fibrosis.
We provide funding for and accredit more than 120 care centers and 53 affiliate programs nationwide. The high quality of specialized care available throughout the care center network has led to the improved length and quality of life for people with CF.
The Cystic Fibrosis Foundation provides standard care guidelines based on the latest research, medical evidence, and consultation with experts on best practices.
As a clinician, you’re critical in helping people with CF maintain their quality of life. We’re committed to helping you partner with patients and their families by providing resources you can use to improve and continue to provide high-quality care.
As part of the Cystic Fibrosis Foundation's mission to help improve the lives of people living with cystic fibrosis, the PSDC initiative taps the CF community to inform key efforts to support the management of daily care.
Your cystic fibrosis care team includes a group of CF health care professionals who partner with you to provide specialized, comprehensive CF care.
Many people living with cystic fibrosis and their families face complicated issues related to getting the care they need. Cystic Fibrosis Foundation Compass makes sure that no one has to do it alone.
CF Foundation Compass is a service that helps people with CF and their families with navigating insurance options, connecting to legal information and experts, finding available financial resources, and tackling other life issues.
CF care team members are paramount in providing highly specialized care to people living with CF. CF Foundation Compass can help by serving as a strategic ally for care teams, so team members can focus on their patients’ care.
CF Foundation Compass can help you navigate insurance, financial, legal, and other issues you are facing. Use this online form to start your conversation with a Compass case manager today.
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for CF and supports a broad range of research initiatives to tackle the disease from all angles.
The CF Foundation offers a number of resources for learning about clinical trials and treatments that are being developed to improve the treatment of cystic fibrosis.
Our understanding of CF continues to evolve as scientists study what causes the disease and how it affects the body. These insights drive the development of new and better treatments and bring us one step closer to a cure.
Researchers, supported by the CF Foundation, have made tremendous advances to improve the health and quality of life of people with CF. We are committed to providing the tools and resources you need to continuously build upon this work.
The recent approval of a game-changing triple-combination therapy and the announcement of a major infusion of research funding are just two reasons why we are at a pivotal time in cystic fibrosis and why this year's North American Cystic Fibrosis Conference in Nashville, Tenn., has been so exciting.
November 1, 2019
CF Care -- Writing the Next Chapter Together
I Have Two Nonsense Mutations. Here’s What a Path to a Cure Means to Me
I have always loved the excitement of the world's largest gathering of cystic fibrosis clinicians and researchers, known as the North American Cystic Fibrosis Conference (NACFC). Nearly 5,000 clinicians and researchers have been taking part in this year's conference in Nashville, Tenn., from Oct. 31-Nov. 2 where they have been learning more about the latest advances in CF research, care, and drug development.
This year has been even more exhilarating with the approval of the triple-combination modulator, the 30th anniversary of the crucial discovery of the gene that causes CF, and the Oct. 30 announcement of the Foundation's Path to a Cure initiative. These milestones provide us with an important opportunity to look ahead at what's next in CF.
The opening to the first plenary featured a tribute to the Foundation's president and CEO Preston Campbell, who will be retiring at the end of the year. Many remarked on Preston's commitment to leading with both his head and his heart throughout his 32 years of working in CF, and mentioned his signature line, “what will this mean for people with CF?”
“Scientific breakthroughs are happening more frequently, giving us new exciting paths to finish our journey,” Campbell said in an emotional speech. “Don't stop dreaming of a day when our journey is over, and all people with CF can say, 'I used to have CF'.”
Michael BoyIe, MD, the Foundation's current senior vice president of therapeutics development -- who will become president and CEO of the Foundation on Jan. 1 -- presented a compelling vision of the future, declaring we are about to enter the most transformative time in the history of CF and that our most important and our most challenging work is ahead of us.
Mike introduced Bill Skach, MD, senior vice president of research affairs at the Foundation, who outlined the Path to a Cure, the Foundation's $500 million research initiative to deliver treatments for the underlying cause of the disease and a cure for every person with cystic fibrosis. Bill explained how the Foundation is challenging academia and industry to accelerate the pace of progress in CF drug discovery and development.
“If the opportunities are there, we will even exceed our $500 million goal. This is not a limit. This is our target,” Bill said. “I'm absolutely convinced that this is a seminal moment in CF. It is rare that we have such an opportunity, and we need to seize that opportunity. We have the vision. We have the resources. And we have the determination.”
Marie Egan, MD, vice chair for research, Department of Pediatrics, Yale School of Medicine, then provided a deep dive into the science in her plenary talk, “Emerging Technologies That Will Lead to CFTR Restoration in All People With CF.” Dr. Egan discussed emerging, cutting-edge therapies, including novel approaches for people with nonsense mutations, as well as the challenges and opportunities that lie ahead as we work to develop novel genetic-based therapies.
In the second plenary, “Entering the Era of Highly Effective Modulator Therapy,” Jane Davies talked about the evolution of CFTR modulators and the potential benefits of introducing them to younger individuals. She also mentioned a new clinical trial called PROMISE that will study the short- and long-term effects of the new triple-combination therapy on the overall health of people with CF.
In addition, she highlighted a future study called SIMPLIFY that will examine reduced treatments in people with CF after they start highly effective modulators. Dr. Davies said treatment burden was the No. 1 research priority of people with CF in Europe, and I know it rated highly in surveys that have been conducted by the Foundation in the U.S.
Out of the many highlights from the first two plenaries, it was nice to end on a high note -- literally -- with a song from Dr. Francis Collins, the director of the National Institutes of Health and one of three researchers who co-discovered the CFTR gene in 1989. This breakthrough charted the path for the CF scientific community.
“We did dream back in 1989 that that discovery would have consequences. We didn't know what that pathway would look like. We didn't know how long the journey might be. It is remarkable to be able to be here in Nashville today and to say for 90 percent, we have arrived at a remarkable milestone,” Collins said, before singing a song that he wrote, “Dare to Dream.” “I am confident that we're not done yet. We're just getting started.”
Vice President of Clinical Research, Cystic Fibrosis Foundation
JP is the vice president of clinical research for the Cystic Fibrosis Foundation and a professor of pediatric pulmonary medicine at Cincinnati Children’s Hospital Medical Center. His role at the Foundation is to oversee clinical research conducted by the Foundation’s Therapeutics Development Network and investigators from academic institutions internationally. He also is deeply involved in the education and training of physician-scientists and career development in CF research. JP has over 250 peer-reviewed publications and regularly provides leadership in clinical and translational research through the international CF research community.
Share this Post
This site contains general information about cystic fibrosis, as well as personal insight from the CF community. Opinions and experiences shared by members of our community, including but not limited to people with CF and their families, belong solely to the blog post author and do not represent those of the Cystic Fibrosis Foundation, unless explicitly stated. In addition, the site is not intended as a substitute for treatment advice from a medical professional. Consult your doctor before making any changes to your treatment.
Follow Us On
Insurance, financial, legal, and other issues. A dedicated, knowledgeable CF Foundation Compass case manager is ready to work with you one-on-one.
Cystic Fibrosis Foundation
4550 Montgomery Ave.
Suite 1100 N
Bethesda, MD 20814
800-344-4823 (toll free)
Sign up for our emails